Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors

Inclusion Criteria: Consenting patients (age \< 70) will be eligible for participation in the study involving selective anti-tumor immunotherapy provided the following criteria are met: * Evidence of cancer not expected to be cured with conventional modalities * Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 and sarcomas. Adult patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and selected cases of ovarian cancer, gastrointestinal cancer, small-cell and non-small cell lung cancer with non-bulky metastatic disease, and metastatic prostate cancer. * Patients with measurable disease evaluable for response with anticipated life expectancy \> 3 months. * Patients must be \> 2 weeks off of anti-cancer or potentially immunosuppressive treatment. * Adequate ambulatory performance status (Karnofsky \> 80%; ECOG 0-1) to enable outpatient treatment. * Compliant and cooperative patients anticipated to be evaluable for response according to the investigator's assessment. * HLA-compatible (fully matched or single locus mismatched) donor available for allogeneic stem cell transplantation. Exclusion Criteria: * Patients with bulky disease or patients with brain metastases resistant to chemo-radiotherapy. * Patients with a significant history or current evidence of potentially severe cardiovascular or lung disease, or other disease or clinical condition that may not permit accomplishing the planned treatment or drawing conclusions. * Hepatic and/or renal failure. * Evidence of serious active infection requiring antibiotic therapy. * Pregnancy. * Contraindication for donation due to donor disease: HIV-1; hepatitis B surface antigen (HBsAg) positivity.